Close X
Attorney Spotlight

Find out how Gardner Bell's experience promoting financial and economic development initiatives both locally and abroad informs his role as an attorney. Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Michael R. Hess

Member

Memphis
(901) 543-5713 TEL
(800) 543-3422 FAX

Michael R. Hess

Member

Memphis
(901) 543-5713 TEL
(800) 543-3422 FAX
Memphis
(901) 543-5713 TEL
(800) 543-3422 FAX

Michael Hess leads the firm's Specialty Pharmacy & Pharmaceuticals Practice Group. His ability to balance legal issues with business issues has earned him a reputation as a go-to lawyer in the specialty pharmacy industry.

Mike's ability to provide practical and impactful advice to specialty pharmacies is rooted in his first-hand experience as former Chief Counsel & VP of Strategic Development of Accredo Health Group, former Assistant General Counsel of Medco Health Solutions and as a private practice attorney to the industry. He now supports 40 percent of the largest independent specialty pharmacy companies located from Los Angeles to Orlando, serving as the outside general counsel. In addition, he has participated in many of the specialty pharmacy transactions coming to market during the past three years. Mike's strategic business advice and transactional and regulatory guidance helps manufacturers and pharmacies get high-cost, complex specialty drugs from the manufacturer's warehouse to the patient's door, safely, legally, effectively and efficiently.

Michael Hess leads the firm's Specialty Pharmacy & Pharmaceuticals Practice Group. His ability to balance legal issues with business issues has earned him a reputation as a go-to lawyer in the specialty pharmacy industry.

Mike's ability to provide practical and impactful advice to specialty pharmacies is rooted in his first-hand experience as former Chief Counsel & VP of Strategic Development of Accredo Health Group, former Assistant General Counsel of Medco Health Solutions and as a private practice attorney to the industry. He now supports 40 percent of the largest independent specialty pharmacy companies located from Los Angeles to Orlando, serving as the outside general counsel. In addition, he has participated in many of the specialty pharmacy transactions coming to market during the past three years. Mike's strategic business advice and transactional and regulatory guidance helps manufacturers and pharmacies get high-cost, complex specialty drugs from the manufacturer's warehouse to the patient's door, safely, legally, effectively and efficiently.  

His practice involves a range of legal counseling for leaders in the pharmacy industry, including:

  • Specialty Pharmacy – Helping large and small specialty pharmacies develop their businesses through contract negotiation and counseling on regulatory and operational requirements.
  • Drug Distribution – Providing legal, regulatory and negotiation support related to the supply chain to specialty and retail pharmacies, wholesale distribution centers, reimbursement hub services, co-pay and coupon program services, adverse event or clinical hotline services, and associated software and program design agreements.
  • 340B Pharmacy Contracts – Structuring contract arrangements for hospitals, FQHCs, Ryan White Clinics and hemophilia treatment centers to access 340B discounted drugs for eligible patients.
  • Transactional Support – Advising private equity firms and strategic buyers in the identification, evaluation, bid process, diligence and acquisition of potential specialty pharmacy and acquisition targets.

Previously, Mike was a shareholder of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC where he led the firm's Drug, Device & Life Sciences industry team.

+ Read More

- Read Less

Memberships

American Health Lawyers Association (AHLA) — RAP Practice Group, Vice Chair (2004-2007)

Institute for Health Law & Policy (iHeLP), University of Memphis Cecil C. Humphreys School of Law — Advisory Board 

Memphis Leadership Academy — Board of Trustees

National Infusion Center Association — Advisory Board

Make-a-Wish of the Mid-South — Board of Directors

News

View More

Representative Experience

View More

Publications

View More

Upcoming Events

Past Events

View More

Media Mentions

View More

Additional Thought Leadership

Recent Presentations:

  • Panelist – "Understanding the Contractual, Operational, Regulatory Nuances of Specialty Pharmacy Contracting," The World Congress Summit on Specialty Market Access and Channel Optimization (July 2014)
  • Presenter – "Specialty Drugs & Limited Distribution Networks Roundtable," 17th Annual 340B Coalition Conference (July 2014)
  • Panelist – "Specialty Pharmacy Issues Impacting Oncology Practices," Oncology Circle Annual Meeting (October 2013)
  • Moderator – "Specialty Pharmacy Mergers & Acquisitions (MA): Trends, Strategies, and Opportunity," National Association of Specialty Pharmacies Strategic Business Exchange (October 2013)
  • Moderator – "340B in the Trenches: What You Should Know About 340B Audits," American Health Lawyers Association (August 2013)
  • Presenter – "Specialty Drugs & Limited Distribution Networks Roundtable," 17th Annual 340B Coalition Conference (July 2013)
  • Presenter – "Current Oncology Practice Trends," Oncology Physician Resources 2013 Annual Meeting (May 2013)
  • Panelist – "Ongoing Controversies in 340B," Pharmaceutical Care Management Association - 2013 Specialty Pharmacy Business Forum (March 2013)
  • Panelist – "How to Structure 340B Contract Pharmacy Agreements," American Bar Association webcast (September 6, 2012)
  • Presenter – "Specialty Drugs & Limited Distribution Networks," 16th Annual 340B Coalition Conference (July 2012)
  • Presenter – "Nuts & Bolts of Contract Pharmacy Implementation and Compliance," 8th Annual 340B Coalition Winter Conference (March 2012)
  • Presenter – "Drug Supply Policy, Challenges & Solutions," 8th Annual 340B Coalition Winter Conference (March 2012)

Recent Article:

  • Co-author – "HHS Issues Guidance on Permitted Remuneration for Prescription Refill Reminders in the Absence of Patient Authorization," Health Lawyers Weekly (October 11, 2013)

Accolades

Chambers USA — Healthcare (2016)

BTI Client Service All-Stars (2016)

Martindale-Hubbell — AV Preeminent® Peer Review Rated

Best Lawyers in America® — Health Care Law (2014-2017)

Mid-South Super Lawyers (2009)

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.